
According to leading export promotion body of Pharmaceuticals, Pharmexcil, Indian pharma exports are estimated to have grown, but at a slower pace of 2.2 per cent to about $15.2 billion during the financial year ended March 2015 against $14.9 billion in the previous fiscal.
As suggested by leading daily, PV Appaji, Director General, Pharmaceuticals Export Promotion Council (Pharmexcil) said the depreciation of Russian rouble, coupled with the Ukraine situation led to a de-growth of overall pharma exports, despite of a solid rise in the US market.
Last year, Appaji said that the growth in the US would be around 13 per cent despite various regulatory issues compared with 18 per cent earlier.
"Also, some of our Indian companies have opened their 100 per cent subsidiaries in other countries in which case the export of goods is shown as stock transfer," Appaji added.
Appaji said that in a bid to penetrate Japanese generic drug market, which is said to be the second-largest drug market after the US, the Indian government is trying to convince Japanese drug makers about the capabilities of Indian pharma industry through 'Brand India' campaign.
Reportedly, replying to a query on GVK Bio, which earned the wrath of the European Union for alleged violations of norms in clinical studies undertaken by the Hyderabad-based firm, Appaji said the government fully supports the firm and may take up the issue with appropriate international agencies.